title: Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
authors.affiliation: Institute of Pathology, University of Cologne, Cologne, Germany. hm.kvasnicka@uni-koeln.de
authors.forename: Hans Michael
authors.initials: HM
authors.lastname: Kvasnicka
authors.forename: Juergen
authors.initials: J
authors.lastname: Thiele
authors.forename: Annette
authors.initials: A
authors.lastname: Schmitt-Graeff
authors.forename: Volker
authors.initials: V
authors.lastname: Diehl
authors.forename: Norbert
authors.initials: N
authors.lastname: Niederle
authors.forename: Hans Eckart
authors.initials: HE
authors.lastname: Schaefer
mesh_terms: D001853:Bone Marrow / Q000473:pathology*; D015672:Erythroid Precursor Cells / Q000187:drug effects; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000494:pharmacology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011379:Prognosis; D011994:Recombinant Proteins; D018570:Risk Assessment; D016019:Survival Analysis
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006918:Hydroxyurea